FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2
  • Home
  • About
  • Projects
    • P1 Lymph-Transplant
    • P2 Modulators of LA
    • N1 Ocular GvHD
    • N2 ABCB5 & Pterygium
    • P4 Ocular Melanoma
    • P5 Myeloid Cells
    • P6 Microglia in AMD
    • P8 Uveitis
    • C1 Eye Imaging
    • C2 Management
    • Publication highlights
  • Team
    • Executive Board
    • Research Groups
    • Central Projects
    • Associated projects
    • Alumni
  • Links
  • Events
    • Guest lectures
    • Retreats
    • Symposium
  • News
✕

Aniridie – new project against blindness

Aniridie is a rare but very serious inherent eye disease which is difficult to treat. The iris of the affected is incomplete or has not been formed at all during pregnancy, additionally, patients often suffer from a vascularized, dull cornea. It is not seldom that patient has a deformity of their retina, both can cause blindness if not treated properly.

The European Union (EU) supports within the European Cooperation in Science and Technology – Program (COST) the project Aniridia-net from 2019 to 2023 in order to get a better understanding and to develop new therapeutic options.

Aniridai-Net is a European wide bottom-up- network including scientist, ophthalmologists, interns, Aniridie – patient organisation, industry and special groups of interest conducted by Univ. Univ.-Prof. Dr. Claus Cursiefen, Chairman, Department of Ophthalmology, University of Cologne and Prof. Dr. Neil Lagali, University Linköping in Sweden.

The objective of this program is to improve the clinical management of the disease, support of innovative science, as well as the development of new alternatives for diagnostic and therapy. A great focus of research lies within the stem cell studies which along with other research fields complement the DFG Research Unit FOR 2240 at the Department of Ophthalmology at the University Hospital of Cologne.

Related posts

FOR 2240 ARVO 2022

FOR 2240 ARVO 2022

June 3, 2022

FOR 2240 scientists receive several honors at ARVO 2022


Read more
DOG Rokohl

DOG Rokohl

March 22, 2022

FOR 2240 Scientist Dr. Alexander C. Rokohl was awarded the Brewitt Publication Prize


Read more
RWA Schlereth 2022

Augenklinik RWA Schlereth 2022

February 18, 2022

Dr. Simona Schlereth wins RWA Science Award 2022


Read more

News

  • FOR 2240 scientists receive several honors at ARVO 2022
  • FOR 2240 Scientist Dr. Alexander C. Rokohl was awarded the Brewitt Publication Prize
  • Dr. Simona Schlereth wins RWA Science Award 2022
  • Dr. Yongwei Guo wins DOG Doctoral Award for outstanding dissertation
  • FOR 2240 scientist Dr. Alexander Rokohl wins DOG Science Prize “Dry Eye and Blepharitis/MGD”

More information

  • Publication highlights
  • Jobs
  • Contact
  • Impressum
  • Datenschutz

Newest publications

Supplemental Anti Vegf A-Therapy Prevents Rebound…(2020)


Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human…(2020)


Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional…(2020)


Contact

Esther Engel
Management Office
DFG Research Unit FOR2240
Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50937 Cologne, Germany

www.for2240.de

Tel. +49 (0)221 478 32845
Fax. +49 (0)221 478 5094
esther.engel@uk-koeln.de

Partnerlogos

© 2021 FOR2240 | Online Marketing von Resulted Lübeck